Bob Lutz
Company: Iksuda Therapeutics
Job title: Chief Scientific Officer
Seminars:
Opportunity to be First-in-Class: Considerations for Collaborations with New Targets 11:40 am
What are the economics of having a new target for others to develop an ADC around? Discussing opportunities to be first-in-class pursuing underexploited targets Debating the decision to leverage the best linker-payload platform or off-patent technologies, considering the influence on the side effect profileRead more
day: Conference Day Two
Chair’s Opening Remarks 7:30 am
day: Conference Day Two